| A Study to Evaluate the Effects of KP-001 on the QT/QTc Intervals in Healthy Adults (NCT06649942) | Kaken Pharmaceutical | 2024-10-01 |
| Interstitial Photodynamic Therapy Following Palliative Radiotherapy in Treating Patients With Inoperable Malignant Central Airway Obstruction (NCT06306638) | Roswell Park Cancer Institute | 2024-10-01 |
| SB: Promoting Bone Health in Women (NCT06843486) | Instituto Politécnico de Bragança | 2024-10-01 |
| An Investigational Scan (124I-hJAA-F11 PET/CT) for Diagnosing Lung Cancer (NCT06427369) | Roswell Park Cancer Institute | 2024-10-01 |
| A Relative Bioavailability and Food Effect Study of HDM1002 in Healthy Subjects (NCT06608329) | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | 2024-10-01 |
| A Phase I Study to Assess the Tolerability of 225Ac-DOTATATE in Patients With Refractory and Relapsing Multiple Myeloma Expressing Somatostatin Receptors (NCT06411301) | Jules Bordet Institute | 2024-10-01 |
| SBI for PSM and PSD (NCT06923384) | California State University, Long Beach | 2024-10-01 |
| Hypofractionation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma (NCT06344130) | National Cancer Institute (NCI) | 2024-10-01 |
| Phase 1/2 Study of Autologous SCG142 TCR T Cells in Patients With HPV16/52-positive Carcinoma (NCT06505551) | SCG Cell Therapy Pte. Ltd. | 2024-10-01 |
| Use of Pulsatile Intravenous FSH to Mitigate Reprometabolic Syndrome (NCT06414096) | University of Colorado, Denver | 2024-10-01 |
| Clinical Study of Therapeutic Immunological Agent for EBV Lymphoproliferative Diseases (NCT06666153) | West China Hospital | 2024-10-01 |
| APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML (NCT06634394) | Aptevo Therapeutics | 2024-10-01 |
| Can Drospirenone be Used to Prevent LH Surge in Controlled Ovarian Stimulation in PCOS?! (NCT06608186) | Ahmed Saad | 2024-10-01 |
| Azacytidine Plus CAOLD Regimen in Relapsed/Refractory Peripheral T-Cell Lymphomas (NCT06176027) | Navy General Hospital, Beijing | 2024-10-01 |
| Dexamethasone Use in Pediatric Rhabdomyolysis Patients in Addition to Standard Protocols (NCT06429982) | Children's National Research Institute | 2024-10-01 |
| Esomeprazole Magnesium Dihydrate 40 mg Tablets Relative to Nexium 40 mg Tablets Under Fed Condition (NCT06233149) | Bio-innova Co., Ltd | 2024-10-01 |
| A Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of Xanomeline With Trospium Chloride Versus KarXT in Healthy Adult and Elderly Participants of Japanese Ethnicity and to Assess the Effect of Omeprazole on the PK of Xanomeline With Trospium Chloride in Healthy Adult Participants (NCT06605950) | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | 2024-10-01 |
| Motivational Interviewing Intervention For Risky Drinking Treatment Among Indigenous Population (NCT06583356) | Department of Public Health Medicine, MARA University of Technology | 2024-10-01 |
| 177Lu-PSMA, Niraparib/AA Plus Prednisone for Prostate Cancer (NCT06329830) | Baptist Health South Florida | 2024-10-01 |
| Effect Of Sodium Glucose Co-Transporter-2 (SGLT-2) Inhibitors on Body Mass Index After 3 Months of Use in Diabetic Patients (NCT07367555) | Ariba Shafiq | 2024-10-01 |
| Role of Enteral Lactoferrin as an Adjuvant for Prevention of Sepsis Among Preterm Neonates (NCT07480434) | Zartash Sial Paeds Med | 2024-10-01 |
| Clinical Evaluation of [177Lu]Lu-BQ7876 for Targeting of Prostate-Specific Membrane Antigen (NCT06641219) | Tomsk National Research Medical Center of the Russian Academy of Sciences | 2024-10-01 |
| A Study to Evaluate the Pharmacokinetics and Safety of K-808 (Pemafibrate) in Subjects With Primary Biliary Cholangitis With Compensated Cirrhosis and Without Cirrhosis. (NCT06525311) | Kowa Research Institute, Inc. | 2024-10-01 |
| CD19/CD22 CAR-T Cell Therapy in MRD-Positive B-lineage Acute Lymphoblastic Leukemia in Children. (NCT06752785) | Guangzhou Women and Children's Medical Center | 2024-10-01 |
| SHR-1501 Combined With SHR-2005 for High-Risk Non-Muscle Invasive Bladder Cancer Which is Not Completely Resectable by TURBt (NCT06588179) | Fudan University | 2024-10-01 |
| Infliximab Therapy for Dolichoectactic Vertebrobasilar Aneurysms (NCT02638701) | University of California, San Francisco | 2024-10-01 |
| PETMRI for Chronic Pain from Spinal or Peripheral Nerve Origin (NCT06599151) | Stanford University | 2024-10-01 |
| AK112 Plus Platinum-based Chemotherapy for EGFR/ALK/ROS1 Positve NSCLC (NCT06196814) | Hunan Province Tumor Hospital | 2024-10-01 |
| Digital Techniques (NCT06805604) | Faculty of Dental Medicine for Girls | 2024-10-01 |
| A Randomized, Placebo-controlled Trial of Prednisone in Refractory Restless Legs Syndrome: a Pilot Study (NCT06631300) | Scripps Health | 2024-10-01 |
| Clinical Study to Evaluate the Possible Efficacy and Safety of Diosmin and Hesperidin Combined Therapy in Patients With Helicobacter Pylori Infection (NCT06546111) | Sadat City University | 2024-10-01 |
| A Drug-Drug Interaction (DDI) Study of HDM1002 With Repaglinide, Atorvastatin, Digoxin and Rosuvastatin in Healthy Subjects and Overweight Subjects. (NCT06601517) | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | 2024-10-01 |
| A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD) (NCT06551142) | GlaxoSmithKline | 2024-09-30 |
| Study of RN0361in Adult Healthy Subjects and Adult Hypertriglyceridemic Subjects (NCT06471543) | Ikaria Bioscience Pty Ltd | 2024-09-30 |
| Assessment of Gastrointestinal Blood Loss After Receiving Aspirin or Aspirin Plus Rivaroxaban, or Aspirin Plus REGN9933, or Aspirin Plus REGN7508 in Healthy Adult Participants (NCT06444178) | Regeneron Pharmaceuticals | 2024-09-30 |
| A Phase 1 Dose Escalation Study of VX-973 in Healthy Participants (NCT06615570) | Vertex Pharmaceuticals Incorporated | 2024-09-30 |
| A Study to Evaluate C-CAR031 in Glypican-3 (GPC3)+ Advanced/Recurrent Hepatocellular Carcinoma (HCC) (NCT06590246) | Shanghai AbelZeta Ltd. | 2024-09-30 |
| Trastuzumab Deruxtecan(T-DXd) and Afatinib Combination in HER2-low Advanced Gastric Cancer (NCT06085755) | Jeeyun Lee | 2024-09-30 |
| Study of VG2025 Delivered Intraperitoneally in Patients With Advanced Solid Tumors With Carcinomatosis (NCT06365918) | M.D. Anderson Cancer Center | 2024-09-30 |
| A Study on the Safety and Immune Response to an mRNA-based RSV Investigational Vaccine in Healthy Adults Aged 18-45 Years (NCT06573281) | GlaxoSmithKline | 2024-09-30 |
| Pharmacokinetics and Safety Profiles After Administration of DA-5221_01 and Co-administration of 5221_01-R1 and DA-5221_01-R2 in Healthy Adult Volunteers (NCT06616883) | Dong-A ST Co., Ltd. | 2024-09-30 |
| Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Adizutecan (ABBV-400) Moves Through the Body of Adult Participants With Unresectable Locally Advanced/Metastatic Colorectal Cancer (NCT06464692) | AbbVie | 2024-09-30 |
| A Phase I/II Multicenter, Open-Label Study of Lu-177-DOTAGA-IAC, for the Treatment of Angiogenic Breast Cancer Patients. (NCT04469127) | Advanced Imaging Projects, LLC | 2024-09-30 |
| A Study in Healthy Men to Test How BI 1839100 is Taken up and Handled by the Body (NCT06572111) | Boehringer Ingelheim | 2024-09-30 |
| The Combination of Adebrelimab, Apatinib, and Lrinotecan Liposome for Second-line Treatment of Advanced Gastric Cancer (NCT06592287) | Xianglin Yuan | 2024-09-30 |
| A Study of Mesothelin-Targeted CAR T-Cell Therapy in People With Esophagogastric Cancer (NCT06623396) | Memorial Sloan Kettering Cancer Center | 2024-09-30 |
| Calculating Wall Shear Stress in Infant Pulmonary Veins (NCT06440408) | Children's Hospital of Philadelphia | 2024-09-30 |
| A First in Human Study to Evaluate the Safety and Immunogenicity of RBM-001 in Healthy Adult Volunteers (NCT06878170) | Rock BioMedical, Inc. | 2024-09-30 |
| A Study to Evaluate the Effect of Itraconazole on the Concentration of GSK3923868 in the Blood in Healthy Participants (NCT06597500) | GlaxoSmithKline | 2024-09-30 |
| Assessment of Quizartinib Pharmacokinetic in Subjects With Severe Hepatic Impairment (NCT06740799) | Daiichi Sankyo | 2024-09-30 |
| A Clinical Study of the Safety, Tolerability, Pharmacokinetics, and Initial Efficacy of HRS-4508 Monotherapy in Patients With Advanced or Metastatic Solid Tumors (NCT06598735) | Jiangsu HengRui Medicine Co., Ltd. | 2024-09-30 |
| BTX-A51 in Patients With Liposarcoma or CIC-rearranged Sarcoma (NCT06414434) | Michael Wagner, MD | 2024-09-30 |
| A Study of ZW171 in Participants With Advanced or Metastatic Mesothelin-expressing Cancers (NCT06523803) | Zymeworks BC Inc. | 2024-09-30 |
| A Study of RO7617991 in Patients With Locally Advanced or Metastatic MAGE-A4-Positive Solid Tumors (NCT06372574) | Genentech, Inc. | 2024-09-30 |
| A Phase I Study to Assess the Safety and Efficacy of [225Ac]Ac-DOTATATE in Patients With SSTR+ GEP-Nens (NCT06732505) | Peking University Cancer Hospital & Institute | 2024-09-29 |
| Biological Tumor Infiltrating Lymphocytes Therapy With Immunotherapy for Colon and Rectum Cancer (NCT06530303) | Essen Biotech | 2024-09-29 |
| Evaluating the Safety and Pharmacokinetics of Multiple Ascending Doses of Lucid-21-302 in Healthy Adult Participants (NCT06595706) | Huge Biopharma Australia Pty Ltd | 2024-09-28 |
| A Phase I Dose-escalation Trial of Definitive Single Dose Stereotactic Body Radiotherapy in Low-risk Breast Cancer Patients: DESERT I Trial (NCT06671691) | Universitat de les Illes Balears | 2024-09-27 |
| Study to Assess the Tolerability, Safety and Efficacy of GP681 Powder for Oral Suspension (NCT06643156) | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | 2024-09-27 |
| CD19x22 Chimeric Antigen Receptor T-cell Therapy (CAR T) in Pediatric B-ALL (NCT06559189) | University of Colorado, Denver | 2024-09-27 |
| A Phase 1b Trial to Evaluate the Safety of MB310 in Patients With Active, Mild-to-Moderate Ulcerative Colitis (NCT06582264) | Microbiotica Ltd | 2024-09-27 |
| A Study to Learn How Different Amounts and Forms of the Study Medicine Called PF-06414300 Act in Healthy Adults (NCT06659250) | Pfizer | 2024-09-27 |
| First-in-human Trial of EGL-001 in Patients with Selected Advanced And/or Metastatic Solid Tumors (NCT06622486) | Egle Therapeutics | 2024-09-27 |
| A Phase Ib Study of AZD5462 on Top of Dapagliflozin in Participants With Heart Failure and Moderate Renal Impairment (NCT06639087) | AstraZeneca | 2024-09-27 |
| A Study of SHR-A2102 in Combination With Adebrelimab and SHR-8068 in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NCT06589778) | Shanghai Hengrui Pharmaceutical Co., Ltd. | 2024-09-27 |
| Enhancing the Effects of Alcohol Treatment With L-Carnitine (NCT05355311) | Brown University | 2024-09-27 |
| Study to Assess Relative Bioavailability of GP681 Formulations in Healthy Chinese Male Subjects (NCT06678542) | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | 2024-09-27 |
| Genistein in trAnSthyretin recePtor Amyloid caRdiomyopathy (NCT06634108) | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 2024-09-27 |
| Vaporized Cannabis Administration and Co-Administration of Alcohol on Impairment (NCT06293040) | Johns Hopkins University | 2024-09-26 |
| A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BCX17725 (NCT06539507) | BioCryst Pharmaceuticals | 2024-09-26 |
| A Study of Niraparib in Combination With Abemaciclib for Late Line Treatment of Ovarian Cancer (NICHOL TRIAL) (NCT06594679) | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 2024-09-26 |
| Lamivudine for Solid Tumors (NCT06494579) | Thomas Marron | 2024-09-26 |
| A Mass Balance Study of TS-172 in Healthy Adult Subjects (NCT06596356) | Taisho Pharmaceutical Co., Ltd. | 2024-09-26 |
| Study of YK012 in B-cell Acute Lymphoblastic Leukemia (NCT06580301) | Excyte Biopharma Ltd | 2024-09-25 |
| A Study on the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RS-C1001 Tablets in Chinese Healthy Subjects (NCT06669429) | Peking University First Hospital | 2024-09-25 |
| Combination Therapy for Recurrent Ovarian Cancer (NCT05610735) | Sham Sunder Kakar | 2024-09-25 |
| An Open-label Study in Healthy Participants to Evaluate AZD0780 as an Object or Precipitant of CYP3A4-mediated Drug-drug Interactions (NCT06671405) | AstraZeneca | 2024-09-25 |
| A Study of V118 Formulation C (V118C) in Healthy Participants (V118C-001) (NCT06611033) | Merck Sharp & Dohme LLC | 2024-09-25 |
| Bioequivalence Study of Dabigatran Etexilate Capsules 150 mg in Healthy Thai Volunteers Under Fasting Conditions (NCT06441916) | International Bio service | 2024-09-25 |
| Pharmacokinetic Study of Oligonucleotides in Maixuekang Capsules (NCT06823895) | Nanfang Hospital, Southern Medical University | 2024-09-25 |
| Phase 1 Study to Evaluate PK, Safety, and Tolerability of HRS-5041 in Healthy Caucasian Male Participants (NCT06559007) | Atridia Pty Ltd. | 2024-09-25 |
| Thorough QT/QTc (TQT) Clinical Study to Evaluate the Effects of Ziresovir on Cardiac Repolarization in Healthy Subjects (NCT06591845) | Shanghai Ark Biopharmaceutical Co., Ltd. | 2024-09-25 |
| A Study to Evaluate the Bioequivalence of Ruxolitinib Extended Release (XR) Tablets With Ruxolitinib Immediate Release (IR) Tablets Administered Orally in Healthy Participants (NCT06555081) | Incyte Corporation | 2024-09-25 |
| A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer (NCT06568094) | Jiangsu HengRui Medicine Co., Ltd. | 2024-09-25 |
| A Phase 1 Study to Evaluate JCXH-108, an mRNA-based Vaccine Against RSV (NCT06564194) | Immorna Biotherapeutics, Inc. | 2024-09-25 |
| Effect of Renal Impairment on Enpatoran Pharmacokinetics (NCT06589713) | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 2024-09-24 |
| A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC) (NCT06530251) | Akeso | 2024-09-24 |
| A Phase 1b Study to Investigate Safety and Tolerability of ARGX-119 in Adult Participants With DOK7-Congenital Myasthenic Syndromes (CMS) (NCT06436742) | argenx | 2024-09-24 |
| Evaluate the Safety and Efficacy of Intrathecal Injection of RJK002 in Patients With Amyotrophic Lateral Sclerosis (NCT06493279) | RJK Biopharma Ltd | 2024-09-24 |
| A Study to Evaluate the Pharmacokinetic, Pharmacodynamic Characteristics and the Safety After Administration by Doses of BR1400-1, BR1400-2, BR1400-3 in Healthy Adult Volunteers (NCT06889064) | Boryung Pharmaceutical Co., Ltd | 2024-09-24 |
| Dutasteride Soft Capsule 0.5 mg Relative to Avodart 0.5 mg Soft Capsule (NCT06233227) | Bio-innova Co., Ltd | 2024-09-24 |
| Evaluation of the Protective Efficacy of TV003 or Previous Zika Infection Against Infection With ZIKV-SJRP Challenge Compared to DENV and ZIKV-naïve Controls Against Infection With ZIKV-SJRP Challenge (NCT06805487) | National Institute of Allergy and Infectious Diseases (NIAID) | 2024-09-24 |
| Trial of THEO-260 in Ovarian Cancer Patients (NCT06618235) | Theolytics Limited | 2024-09-24 |
| Evaluating the Accuracy of Soft Tissue Prediction in Patients With Mandibular Prognathism After Orthognathic Surgery Using Handheld Scanner Versus Optical Scanner A Prospective Clinical Trial (NCT06724497) | Cairo University | 2024-09-24 |
| A Study of GenSci098 in Subjects With Active Thyroid Eye Disease (NCT06569758) | Changchun GeneScience Pharmaceutical Co., Ltd. | 2024-09-24 |
| RC48 Monotherapy or Combination With Envafolimab for CDK12 Alterations mCRPC With Standard Treatment Failure (NCT06663007) | Tianjin Medical University Second Hospital | 2024-09-24 |
| Pharmacokinetic (PK) Characterization of Subcutaneous Tulisokibart (MK-7240-010) (NCT06575595) | Merck Sharp & Dohme LLC | 2024-09-24 |
| A Phase I-II Study of High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Abatacept for the Prevention of Graft-Versus-Host Disease (GVHD) Following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) (NCT06681922) | Northwell Health | 2024-09-23 |
| Phase I Trial Evaluating the Pharmacokinetics of Single Ascending Oral Doses of IRL757 in Healthy Elderly Volunteers (NCT06699628) | Integrative Research Laboratories AB | 2024-09-23 |
| Clinical Study of HER-096 in Healthy Volunteer Subjects and Patients With Parkinson's Disease (NCT06659562) | Herantis Pharma Plc. | 2024-09-23 |